Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00647764 · ClinicalTrials.gov registry record · Phase 1
Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas
A Phase 1 study, sponsored by Esanex.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT00647764: Completed Phase 1 study, sponsored by Esanex.
NCT00647764 is a Phase 1 study that has completed, run by Esanex. The registered enrollment target is 32 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00647764, a Phase 1 study, has completed, sponsored by Esanex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
Interventions
- DRUG SNX-5422 Mesylate Hsp90 inhibitor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
What the finished NCT00647764 record still lists
NCT00647764 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (47% lower).
The record links to 0 conditions, and to 1 intervention - of which SNX-5422 Mesylate Hsp90 inhibitor is the first listed.
NCT00647764 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00647764 about?
NCT00647764 is a clinical study titled "Safety Study Of SNX-5422 To Treat Solid Tumor Cancers And Lymphomas". Hsp90 is a chemical in the body that is involved in promotion of cancer. SNX-5422 is an experimental drug that blocks Hsp90. It is being evaluated for safety and efficacy in patients with cancer.
What is the current status of trial NCT00647764?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2008-03. Estimated completion is 2010-09.
What interventions are being tested in trial NCT00647764?
The interventions under investigation include: SNX-5422 Mesylate Hsp90 inhibitor (DRUG).
Who is sponsoring clinical trial NCT00647764?
This trial is sponsored by Esanex, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00647764's enrollment target sits among peer trials
32 1296th of 2000 higher than 679 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia